ClinicalTrials.gg
CompletedNCT05979454Updated Nov 20, 2026

Value of KL-6 in Rheumatoid Arthritis-Associated ILD

An observational study in Rheumatoid Arthritis-Associated Interstitial Lung Disease, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Assiut University · Observational

How we know

Updated Nov 20, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
95
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Arthritis, Rheumatoid by Assiut University — 22 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Assiut University.

Enrollment
15th of 43
95 · median 80
Started
2023
with 5 others
Observational
43 of 49
21 open now
Registered
28th of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by Assiut University, this one is the 15th largest by enrollment of the 43 observational ones that give a count, is one of 6 that started in 2023, is one of 43 observational ones, and was the 28th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

22 of the 49 studies in Arthritis, Rheumatoid by Assiut University are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by Assiut University, or all of them as a file.
02

Study summary

Evaluation of serum KL6 level in rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Read the detailed description

Rheumatoid arthritis (RA) is one of the most common connective tissue diseases (CTD). Its prevalence is increasing worldwide . It is responsible for a considerable number of hospital visits in Egyptian Hospitals . Pumlonary involvement is common in rheumatoid arthritis (RA). Interstitial lung disease associated rheumatoid arthritis (ILD-RA) is responsible for significant morbidity and mortality .

Krebs von den Lungen 6 (KL-6) is a mucin like glycoprotein that is found mainly on the surface of type II pneumocytes as well as in bronchiolar epithelial cells . It has chemotactic and anti-apoptotic action on fibroblasts , hence, it is considered as a marker of pulmonary epithelial cell injury .

Krebs von den Lungen-6 (KL6) has been found to be a valuable diagnostic tool in many interstitial lung diseases. KL6 was found to be a valuable prognostic marker, as well as a marker for disease severity in idiopathic pulmonary fibrosis (IPF) . KL6 was found useful as well in predicting in-hospital mortality in patients with Acute exacerbation of interstitial lung disease (AE-ILD) . KL-6 serum level can serve as a diagnostic marker for connective tissue disease-associated interstitial lung disease (CTD-ILD). It can be used to monitor effectiveness of medical treatment and patient response to pulse therapy . Its value in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) has not yet been adequately investigated.

03

Conditions studied

  • Rheumatoid Arthritis-Associated Interstitial Lung Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

all patients have rheumatoid arthritis-associated interstitial lung disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010.

Inclusion criteria

Inclusion Criteria:

  • all patients have rheumatoid arthritis-associated interstitial lung disease

Exclusion criteria

Exclusion Criteria:

  • Patients with any evidence of infection will be excluded.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
95 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • RA-ILD

    Rheumatoid Arthritis-associated Interstitial Lung Disease

    Diagnostic Test: Krebs von den Lungen-6 (KL6)

  • RA without ILD

    Rheumatoid Arthritis without Interstitial Lung Disease

    Diagnostic Test: Krebs von den Lungen-6 (KL6)

Interventions

  • Diagnostic testKrebs von den Lungen-6 (KL6)

    KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).

    Also known as: Spirometry, HRCT Chest

06

What researchers measure

Primary outcomes

  1. KL-6

    detect its serum level

    Time frame: one day

Secondary outcomes

  1. Spirometry

    FEV1, FVC, FVC/FEV1 will be measured.

    Time frame: one day

  2. HRCT chest

    It will be will be assessed by the radiologist to determine pulmonary involvement.

    Time frame: one day

07

Study locations

1 site
  • Safaa A Eid
    Asyut, Egypt
08

References and documents

Publications

  • Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022 Oct;18(10):591-602. doi: 10.1038/s41584-022-00827-y. Epub 2022 Sep 6. PubMed 36068354 ↗
  • Sakr BR, Elfishawi MM, ElArousy MH, Hatw AK, AbdulKarim AN, Tammam AB, Kotp AN, Hamed ME, Genedy IE, Desouky EDE, Nawito ZO. Rheumatoid arthritis: A single-center Egyptian experience. Immunol Invest. 2018 Apr;47(3):293-302. doi: 10.1080/08820139.2018.1425700. Epub 2018 Jan 16. PubMed 29336618 ↗
  • Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011 Feb 1;183(3):372-8. doi: 10.1164/rccm.201004-0622OC. Epub 2010 Sep 17. PubMed 20851924 ↗
  • Doyle TJ, Lee JS, Dellaripa PF, Lederer JA, Matteson EL, Fischer A, Ascherman DP, Glassberg MK, Ryu JH, Danoff SK, Brown KK, Collard HR, Rosas IO. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest. 2014 Mar 1;145(3):454-463. doi: 10.1378/chest.13-2408. PubMed 24590021 ↗
  • Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, Hiwada K, Ueda N, Akiyama M. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl. 1994;8:81-3. doi: 10.1002/ijc.2910570717. PubMed 8194900 ↗
  • Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol. 1997 Oct;17(4):501-7. doi: 10.1165/ajrcmb.17.4.2253. PubMed 9376125 ↗
  • Arnold DT, Donald C, Lyon M, Hamilton FW, Morley AJ, Attwood M, Dipper A, Barratt SL. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks. PLoS One. 2021 Apr 29;16(4):e0249607. doi: 10.1371/journal.pone.0249607. eCollection 2021. PubMed 33914762 ↗
  • Jiang D, Xiao H, Dong R, Geng J, Xie B, Ren Y, Dai H. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis. Clin Respir J. 2022 Mar;16(3):234-243. doi: 10.1111/crj.13475. Epub 2022 Jan 26. PubMed 35081277 ↗
  • Choi MG, Choi SM, Lee JH, Yoon JK, Song JW. Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease. Sci Rep. 2022 Mar 22;12(1):4916. doi: 10.1038/s41598-022-08965-9. PubMed 35318424 ↗
  • Ma H, Lu J, Song Y, Wang H, Yin S. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease. BMC Pulm Med. 2020 Jan 8;20(1):6. doi: 10.1186/s12890-019-1043-z. PubMed 31915006 ↗
  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584. PubMed 20872595 ↗
  • Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST. PubMed 31613151 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2023 to primary completion in Apr 2024, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Jan 2023 → May 2023, primary completion Dec 2023 → Apr 2024 and completion Dec 2023 → Apr 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 7, 2023
StartActual
May 1, 2023was Jan 2023
Primary completionActual
Apr 1, 2024was Dec 2023
CompletionActual
Apr 1, 2024was Dec 2023
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Safaa A Eid · Asyut, Egypt
Show 1 removed
  • Safaa A Eid · Assiut, Egypt
Nov 20, 2026
Start date
Jan 1, 2023→May 1, 2023
Nov 20, 2026
Primary completion
Dec 2023→Apr 1, 2024 (actual)
Nov 20, 2026
Study completion
Dec 2023→Apr 1, 2024 (actual)
Nov 20, 2026
Enrollment
80 (estimated)→95 (actual)
Nov 20, 2026
Interventions
Arms added: RA-ILD·RA without ILD; arms removed: Rheumatoid Arthritis-associated Interstitial Lung Disease
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Safaa A Eid · Asyut, Egypt
    Show 1 removed
    • Safaa A Eid · Assiut, Egypt
    Start date Jan 1, 2023→May 1, 2023
    Primary completion Dec 2023→Apr 1, 2024 (now actual)
    Study completion Dec 2023→Apr 1, 2024 (now actual)
    Enrollment 80 (estimated)→95 (actual)
    Interventions Arms added: RA-ILD·RA without ILD; arms removed: Rheumatoid Arthritis-associated Interstitial Lung Disease
    + 4 other changes: verification date, design details, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05979454
Lead sponsor
Assiut University
Responsible party
Safaa Abd El-gayed Eid (Principal investigator, Assiut University) — Principal investigator
First posted
Aug 7, 2023
Start date
May 1, 2023
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Last update
Nov 20, 2026

Study contacts

Safaa A Eid, Fellow
principal investigator · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion